Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

about

Efficacy of Thalidomide for Recurrent Gastrointestinal Bleeding due to angiodysplasias in a Hemodialysis Patient.

P2860

Q46880480-0A6A4C9E-DE6E-43F6-BCF7-9CF5E2C7C17E

P2860

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

Item

http://www.wikidata.org/entity/Q35573842

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@ast

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@en

type

Item

label

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@ast

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@en

prefLabel

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@ast

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@en

P1476

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

@en

P2093

Asher Korzets

http://www.w3.org/2001/XMLSchema#string

Avri Chagnac

http://www.w3.org/2001/XMLSchema#string

Boris Zingerman

http://www.w3.org/2001/XMLSchema#string

Uzi Gafter

http://www.w3.org/2001/XMLSchema#string

Valeriya Morduchovitz

http://www.w3.org/2001/XMLSchema#string

Yaacov Ori

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

The biology of VEGF and its receptors

Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.

Thalidomide for treatment of severe intestinal bleeding.

Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.

A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia.

Thalidomide for the treatment of bleeding angiodysplasias.

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.

Von Willebrand's disease and angiodysplasia treated with thalidomide.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

P304

354-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDTPLUS/SFN070

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244892492

http://www.w3.org/2001/XMLSchema#string

P698

25983933

http://www.w3.org/2001/XMLSchema#string

P921

renal dialysis

thalidomide

P932

4421289

http://www.w3.org/2001/XMLSchema#string

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

about

P2860

P2860

Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932